Thromb Haemost 2019; 119(11): 1720-1739
DOI: 10.1055/s-0039-1695770
Review Article
Georg Thieme Verlag KG Stuttgart · New York

From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks

Augusto Martins Lima*
1  Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
,
Ana C. Martins Cavaco*
2  Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany
,
Rodrigo A. Fraga-Silva
1  Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
,
Johannes A. Eble
2  Institute of Physiological Chemistry and Pathobiochemistry, University of Münster, Münster, Germany
,
Nikolaos Stergiopulos
1  Institute of Bioengineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
› Author Affiliations
Funding A.C.M.C. was funded by EU under the People Program (Marie Curie Actions) of the European Union's Seventh Framework Program FP7/2007 -2013/ under the REA grant agreement n° (316610).
Further Information

Publication History

29 March 2019

09 July 2019

Publication Date:
29 September 2019 (online)

Abstract

Despite significant advances in the treatment of thrombogenic diseases, antiplatelet therapies are still associated with a high bleeding risk. Consequently, potential benefits of preventing thromboembolic events by pharmacological agents need to be balanced with the potential harm of inducing hemorrhage. Glycoprotein VI (GPVI) is a platelet-specific receptor, which plays a crucial role in thrombus formation. GPVI deficiency has been identified in patients who suffer from significant reduction of collagen-induced thrombus formation, with a slight tendency for mild bleeding. However, an isolated GPVI deficiency can reduce thrombus formation while not resulting in severe bleeding. Together, these observations strongly suggest that physiological hemostasis does not require GPVI, but pharmacological GPVI modulation may provide novel “bleeding-free” antithrombotic therapies. In this review, we discuss recent findings regarding the biological role of GPVI in platelet-related disorders and highlight the efforts to develop potential therapeutic strategies based on its structure, signaling pathways, and biological effects.

* These authors contributed equally to this work.